the trial should be completed though, whether or not they're having good results. That's the point of the trial. The only extenuating circumstances that SHOULD be in effect are if the drug is actually causing harm versus placebo, in which case the ethical move is to stop administering the drug.
I believe Daval would have had to come clean on that and not have found an excuse-- otherwise every major drug company could get out of failures by inventing protocol aberrations. This does not happen very often, at least with publicly traded companies. See Axonyx and Pharmos Corp for two recent examples of spectacular drug failures that were openly announced.
One other thing to note is that it seems (anecdotally) that Daval's first round of patients were also recruited as investors... well Daval will certainly have to tell their investors why this trial failed and those investors, now significantly less wealthy, will have the story to tell.
Disclaimer: Any information you find on this site should not be considered medical advice. All decisions should be made with the consent of your doctor, otherwise you are at your own risk.